Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Melanoma Clinical Trial

Official title:

Camrelizumab Combined With Anlotinib and Nab-paclitaxel in Patients With Untreated Advanced Mucosal Melanoma:a Single-arm, Multicenter, Open-label Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04979585
• Other study ID #: 2021-ME-01
• Status: Recruiting
• Phase: Phase 2
• Start date: July 15, 2021
• Est. completion date: August 14, 2023

Study information

• Verified date: July 2021
• Source: The First Hospital of Jilin University
• Contact: Di Guo
• Phone: 0431-88782013
• Email: guodi17790060921[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.

Description:

The current traditional cytotoxic single agent or combination chemotherapy cannot clearly improve the overall survival rate of patients with advanced melanoma.From the current point of view, combination therapy will be one of the inevitable trends in the future development of tumor immunotherapy. So carry out this research To evaluate the objective response rate of camrelizumab combined with anlotinib hydrochloride and albumin paclitaxel in the first-line treatment of patients with advanced mucosal melanoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Est. completion date: August 14, 2023
• Est. primary completion date: April 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 years old, gender ;

2. It was confirmed by histopathology that patients with recurrence, unresectable or metastatic mucosal melanoma after surgery (stage III/IV).

3. Have not received any systemic anti-tumor drug therapy in the past, and allow previous adjuvant therapy or neoadjuvant therapy (except PD-1/PDL1 monoclonal antibody and VEGFR TKI), but it is required to be completed at least 4 weeks before the first administration of the study drug, and All related toxic events have returned to normal or CTCAE4.03 grade I or below, except for hair loss).

4. ECOG 0or1?

5. The expected survival time is =12 weeks.

6. Can swallow medicine normally.

7. According to the RECIST 1.1 standard, there is at least one measurable lesion, and the lesion has not been irradiated.

8. Patients are allowed to have a history of brain/meningeal metastasis, but they must undergo local treatment (surgery/radiotherapy) before the start of the study, and be clinically stable for at least 3 months (allowing corticosteroids before the first use of the study drug, but before starting the study drug Need to stop for 2 weeks);

9. Patients have good organ function: no blood transfusion or collection stimulation factors and plateplate production in the 14 days before the first drug was given, neutral granulocyte count =1.5×109/L, plate count= × 80×109/L, hemoglobin =80 g/L, serum creatinine =1.5x normal upper limit (ULN), total bilium =1.5x normal upper limit Value (ULN) ALT, AST=2.5x ULN (no liver transfer) or =5x ULN (e.g. liver transfer), albumin =30 g/L, blood clotting function requirements: international standardized ratio Value (INR= 1.5x ULN, coagulase original time (PT) =1.5x ULN, active partial clotting enzyme time (APTT) =1.5x ULN. Electrolyte requirements: corrected serum calcium, blood potassium,

10. Women of childbearing age must have a negative serum pregnancy test result within 7 days before the first administration of the trial drug; reproductive men or women who are likely to become pregnant must use highly effective contraceptive methods (such as oral contraceptives, uterine contraceptives, etc.) during the entire trial. Internal contraceptive device, sexual desire control or barrier contraception combined with spermicide), and continue contraception for 12 months after the end of treatment.

11. The subjects voluntarily joined the study, signed an informed consent form, had good compliance, and cooperated with the follow-up.

Exclusion Criteria:

1. Patients who have previously received anti-PD-1, anti-PD-L1, anti-PD-L2 therapy and or VEGFR TKI therapy.

2. Patients currently undergoing anti-tumor therapy.

3. Patients who have participated in or are participating in clinical trials of other drugs/therapies within 4 weeks before the first use of the study drug.

4. The study drug has undergone a major surgical operation or has not recovered from the side effects of this operation within 4 weeks before the first administration of the study drug, live vaccination, immunotherapy, and radiotherapy within 2 weeks

5. The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, thyroid Hyperfunction; patients suffering from vitiligo; asthma has been completely relieved in childhood, and can be included in adults without any intervention; patients with asthma that require bronchodilators for medical intervention cannot be included).

6. The patient is using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive purposes (dose>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before enrollment.

7. In the past 5 years, there is a history of other malignant tumors other than mucosal melanoma, except for cured skin basal cell carcinoma, skin squamous cell carcinoma, early prostate cancer and cervical carcinoma in situ.

8. Patients who have received hematopoietic stimulating factors, such as granulocyte colony stimulating factor (G-CSF), erythropoietin, etc., within 1 week before the first administration of the study drug.

9. The HIV antibody or Treponema pallidum antibody test result is positive.

10. Patients with active hepatitis B or C: If HBsAg or HBcAb is positive, add HBV DNA (the test result is higher than the upper limit of the normal range). If the HCV antibody test result is positive, add HCV RNA (the test result is higher than the upper limit of the normal range).

11. Those who are known to be allergic to recombinant humanized PD-1 monoclonal antibody drugs and their components; those who are known to be allergic to anlotinib and any of its excipients; those who are known to be allergic to albumin paclitaxel and its excipients.

12. A large amount of pleural fluid or ascites with clinical symptoms that require symptomatic treatment.

13. Active lung disease (interstitial pneumonia, pneumonia, obstructive lung disease, asthma) or a history of active tuberculosis.

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• Camrelizumab
200mg ,IV,d1,Q3W.
• Anlotinib
8mg,oral, d1-14,Q3W.
• nab-Paclitaxel
260mg/m2,IV,d1,Q3W.

Locations

Country	Name	City	State
China	The first hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Di Wu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	DCR	The percentage of cases that achieved remission (PR+CR) and stable disease (SD) after treatment accounted for the number of evaluable cases.	1 year
Primary	ORR	defined as the proportion of patients whose tumor volume has shrunk to a predetermined value and can maintain the minimum time limit. The sum of complete remission plus partial remission.	1 year
Secondary	PFS	The time from the beginning of randomization to the onset of disease progression or the death of the patient.	1 year